• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Atea Pharmaceuticals, Inc. - common stock (NQ: AVIR )

    3.190 +0.060 (+1.92%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,242,722
    Open 3.120
    Bid (Size) 3.190 (1)
    Ask (Size) 3.280 (6)
    Prev. Close 3.130
    Today's Range 3.110 - 3.315
    52wk Range 2.750 - 4.600
    Shares Outstanding 83,399,377
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study
    Atea Pharmaceuticals reports 98% SVR12 in a Phase 2 hepatitis C study, supporting an eight-week treatment plan with bemnifosbuvir and ruzasvir. 
    Via Benzinga
    Exposures COVID-19

    Performance

    YTD
    -0.62%
    -0.62%
    1 Month
    -5.34%
    -5.34%
    3 Month
    -7.54%
    -7.54%
    6 Month
    -8.60%
    -8.60%
    1 Year
    +0.31%
    +0.31%

    More News

    Read More
    Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    Recap: Atea Pharmaceuticals Q4 Earnings
    Via Benzinga
    Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus
    Via Benzinga
    Exposures COVID-19
    Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus
    Via Benzinga
    Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    AVIR Stock Earnings: Atea Pharmaceuticals Misses EPS for Q1 2024
    Via InvestorPlace
    Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    5 Under 10: Low Share Price, Debt Free, Lots Of Cash
    Via Talk Markets
    Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.